Sugi Predict

Sugi Predict / Compounds / SCHEMBL8207699

SCHEMBL8207699

SCHEMBL8207699

Cc1cc(Cl)ccc1C(C)N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.67
▸ TP53 P04637 1/20 0.67
▸ HTT P42858 1/20 0.67
▸ ADRB2 P07550 1/20 0.46
▸ CYP3A4 P08684 2/20 0.45
▸ PNMT P11086 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ HTR2A P28223 3/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HTR2C P28335 1/20 0.40
▸ HTR2B P41595 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ SCN4A P35499 2/20 0.39
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ SLC6A4 P31645 2/20 0.37
▸ KCNH2 Q12809 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15079741 1.00 LMNA (0.67) LMNATP53HTTADRB2CYP3A4
SCHEMBL23123473 1.00 LMNA (0.67) LMNATP53HTTADRB2CYP3A4
SCHEMBL29757882 1.00 LMNA (0.67) LMNATP53HTTADRB2CYP3A4
Hydrochloric Acid SCHEMBL14120711 0.98 LMNA (0.64) LMNATP53HTTADRB2CYP3A4
SCHEMBL17226299 0.83 HTT (0.45) LMNATP53HTTCYP3A4HTR2A
SCHEMBL1911434 0.82 LMNA (0.48) LMNATP53HTTCYP3A4HTR2A
SCHEMBL8295996 0.81 LMNA (0.48) LMNATP53HTTADRB2CYP3A4
SCHEMBL3317981 0.80 TP53 (1.00) LMNATP53HTTADRB2CYP3A4
SCHEMBL5492924 0.80 TP53 (1.00) LMNATP53HTTADRB2CYP3A4
SCHEMBL3899828 0.80 TP53 (1.00) LMNATP53HTTADRB2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12370192-B2 Azole-fused pyridazin-3(2H)-one derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-07-29 — — US disclosed
EP-4031552-B1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES TAKEDA PHARMACEUTICALS CO (JP) 2024-11-06 — — EP disclosed
CN-112679427-B Tetrahydroisoquinoline derivative, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2023-05-12 — — CN disclosed
US-20230028114-A1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-01-26 — — US disclosed
EP-4031552-A1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES Takeda Pharmaceutical Company Limited (JP) 2022-07-27 — — EP disclosed
CN-114728975-A Azole-fused pyridazin-3 (2H) -one derivatives 武田药品工业株式会社 2022-07-08 — — CN disclosed
US-11142521-B2 Substituted anilines as CCR(4) antagonists CHEMOCENTRYX, INC. (US) 2021-10-12 — — US disclosed
WO-2021055326-A1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 — — WO disclosed
US-20200123139-A1 SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS CHEMOCENTRYX, INC. 2020-04-23 — — US disclosed
US-10407417-B2 Substituted anilines as CCR(4) antagonists CHEMOCENTRYX, INC. (US) 2019-09-10 — — US disclosed
WO-2018022992-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF FLX BIO, INC. (US) 2018-02-01 — — WO disclosed
US-6093851-A N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2000-07-25 — — US disclosed
EP-0735018-B1 N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor SUMITOMO CHEMICAL CO (JP) 1999-07-21 — — EP disclosed
US-5739401-A N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-04-14 — — US disclosed
EP-0735018-A1 N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1996-10-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123139-A1 SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS CCR4, CCR1, CCR3 LMNA 4686/4885TP53 2119/4885HTT 4480/4885
US-20230028114-A1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES GPR139, GPR119, GPR39 LMNA 2280/4885TP53 2590/4885HTT 3419/4885
US-10407417-B2 Substituted anilines as CCR(4) antagonists CCR4, CCR1, CCR3 LMNA 4686/4885TP53 2119/4885HTT 4480/4885
US-12370192-B2 Azole-fused pyridazin-3(2H)-one derivatives GPR139, GPR119, GPR39 LMNA 2280/4885TP53 2590/4885HTT 3419/4885
US-11142521-B2 Substituted anilines as CCR(4) antagonists CCR4, CCR1, CCR3 LMNA 4686/4885TP53 2119/4885HTT 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.